Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Chinese patients with lupus nephritis
NCT05810948Phase 2Completed
- Sponsor
- argenx
- Start
- Feb 2023
- Primary completion
- Jul 2025
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing Efgartigimod IV with Placebo (2 arms). Primary endpoint: Urine Protein Creatinine Ratio at 24 weeks. Started Feb 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05810948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810948.